Showing results (431-440 of 569) with videos related to
Sort By:
Pageof 57
The New England Journal of Medicine|November 13, 2018
Cardiovascular Risk Reduction with Icosapent Ethyl for HypertriglyceridemiaDeepak L Bhatt, P Gabriel Steg, Michael Miller, et al.Alimentary Pharmacology & Therapeutics|April 15, 2020
Mortality and morbidity of locally acquired hepatitis E in the national Scottish cohort: a multicentre retrospective studySebastian J Wallace, Rachael Swann, Mhairi Donnelly, et al.Journal of Clinical Lipidology|August 16, 2017
Metabolic syndrome cluster does not provide incremental prognostic information in patients with stable cardiovascular disease: A post hoc analysis of the AIM-HIGH trialRadmila Lyubarova, Jennifer G Robinson, Michael Miller, et al.The American Journal of Medicine|May 29, 2017
A Deficiency of Nutrition Education and Practice in CardiologyStephen Devries, Arthur Agatston, Monica Aggarwal, et al.Journal of the American College of Cardiology|March 26, 2024
Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent EthylMichael Szarek, Deepak L Bhatt, Michael Miller, et al.Psychiatric Services (Washington, D.C.)|February 9, 2007
Direct care workers in the National Drug Abuse Treatment Clinical Trials Network: characteristics, opinions, and beliefsDennis McCarty, Bret E Fuller, Cynthia Arfken, et al.The International Journal of Behavioral Nutrition and Physical Activity|December 20, 2015
An observational study identifying obese subgroups among older adults at increased risk of mobility disability: do perceptions of the neighborhood environment matter?Abby C King, Deborah Salvo, Jorge A Banda, et al.Atherosclerosis|June 27, 2022
Omega-3 fatty acids, subclinical atherosclerosis, and cardiovascular events: Implications for primary preventionAbdulhamied Alfaddagh, Karan Kapoor, Zeina A Dardari, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|February 16, 2013
Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRKJürgen K Rockstroh, Edwin DeJesus, Jeffrey L Lennox, et al.Circulation|June 28, 2022
Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker SubstudyPaul M Ridker, Nader Rifai, Jean MacFadyen, et al.Pageof 57